CXCL5/ENA-78 ELISA DY254-05 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemCXCL5/ENA-78 ELISA
CompanyR&D Systems, a Bio-Techne Brand
Price $450.00Supplier Page View Company Product Page
Catalog NumberDY254-05
Quantity1 Kit (for 5 Plates) (also 1 Kit (for 15 Plates))
ApplicationsELISA
Detection Range15.60 - 1000 pg/mL
ReactivityHuman
Detection TargetCXCL5/ENA-78
StorageStore the unopened product at 2 - 8 °C. Do not use past expiration date
NCBI Full Gene NameC-X-C motif chemokine ligand 5
NCBI Gene AliasesENA-78, SCYB5

Specifications/Features

Available conjugates: Sizes Available: 1 Kit (for 5 Plates) (also 1 Kit (for 15 Plates))

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Neutrophil Dynamics Contribute to Disease Progression and Poor Survival in Pancreatic CancerCancers (Basel)November 1, 2025Reegan Sturgeon, Paran Goel, Caitlin Molczyk, Ridhi Bhola, Paul M. Grandgenett, Michael A. Hollingsworth, Rakesh K. SinghUSA",M802B,1:200,AB_223584 5,Human,CXCL5ELISA capture antibody,CXCL5,"R&D Systems, Minneapolis, MN, USA",DY254-05,1:500,AB_2245472 6,Mouse,Anti-myeloperoxidase,Neutrophils,"Abcam, Waltham, MA, USA",ab9535,1:200,AB_307322 7,Mouse,Cathepsin

(2) Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic CancerbioRxiv : the preprint server for biologyJune 28, 2025Molczyk C, Sturgeon R, Saxena S, Johnsson E, Bhatia R, Bhyrabhatla N, Kumar S, Batra SK, Singh RK.

(3) Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic CancerBiomoleculesApril 30, 2025Christopher BN, Golick L, Basar A, Reyes L, Robinson RM, Angerstein AO, Krieg C, Hobbs GA, Guttridge DC, O'Bryan JP, et al.specifications. Kits were as follows: Human CXCL1 (88-52122-22, Invitrogen, Waltham, MA, USA), Human CXCL5 (dy254-05, R & D Systems, Minneapolis, MN, USA), Human CXCL8 (88-8086-22, Invitrogen, Waltham, MA, USA), Mouse

(4) SARS-CoV-2 Spike Protein Amplifies the Immunogenicity of Healthy Renal Epithelium in the Presence of Renal Cell CarcinomaCellsDecember 10, 2024Somova M, Simm S, Ehrhardt J, Schoon J, Burchardt M, Pinto PC.kit,Supplier,Reference Human CXCL1/GRO alpha DuoSet,R&D Systems,DY275-05 R&D Systems,Human CXCL5/ENA-78 DuoSet,DY254-05 R&D Systems,Human IL-6 alpha Complex DuoSet,DY8139-05 R&D Systems,HUman IL-8/CXCL8 DuoSet,DY208 R&D Systems

(5) Adipose-Tumor Crosstalk contributes to CXCL5 Mediated Immune Evasion in PDACbioRxiv : the preprint server for biologyAugust 16, 2023Walsh RM, Ambrose J, Jack JL, Eades AE, Bye B, Ruckert MT, Olou AA, Messaggio F, Chalise P, Pei D, et al.

(6) Serum interleukin-6, procalcitonin, and C-reactive protein at hospital admission can identify patients at low risk for severe COVID-19 progressionFrontiers in microbiologyJanuary 1, 2023Zobel CM, Wenzel W, Krüger JP, Baumgarten U, Wagelöhner T, Neumann N, Foroutan B, Müller R, Müller A, Rauschning D, et al.

(7) ADSCs stimulated by resistin promote breast cancer cell malignancy via CXCL5 in a breast cancer coculture modelScientific reportsSeptember 14, 2022Wang YY, Hung AC, Wu YC, Lo S, Chen HD, Chen YK, Hsieh YC, Hu SC, Hou MF, Yuan SF.

(8) Pro-cancerogenic effects of spontaneous and drug-induced senescence of ovarian cancer cells in vitro and in vivo: a comparative analysisJournal of ovarian researchJuly 26, 2022Rutecki S, Szulc P, Pakuła M, Uruski P, Radziemski A, Naumowicz E, Moszyński R, Tykarski A, Mikuła-Pietrasik J, Książek K.

(9) Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinomaAmerican journal of cancer researchJanuary 1, 2022Saxena S, Molczyk C, Purohit A, Ehrhorn E, Goel P, Prajapati DR, Atri P, Kaur S, Grandgenett PM, Hollingsworth MA, et al.

(10) Adipocytokines in Untreated Newly Diagnosed Rheumatoid Arthritis: Association with Circulating Chemokines and Markers of InflammationBiomoleculesFebruary 21, 2021Vasileiadis GK, Lundell AC, Zhang Y, Andersson K, Gjertsson I, Rudin A, Maglio C.

(11) Patient Derived Colonoids as Drug Testing Platforms-Critical Importance of Oxygen ConcentrationFrontiers in pharmacologyJanuary 1, 2021Skovdahl HK, Gopalakrishnan S, Svendsen TD, Granlund AVB, Bakke I, Ginbot ZG, Thorsvik S, Flatberg A, Sporsheim B, Ostrop J, et al.were excluded from further assessment. ELISA kits for human CXCL1 (DY275-05), CXCL2 (DY276-05), CXCL5 (DY254-05), CXCL8 (DY208), CXCL10 (DY266-05), CXCL11 (DY672) and CCL20 (DY360), all from R&D Systems (Abington,

(12) Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-AgonistFrontiers in pharmacologyJanuary 1, 2020Salvator H, Buenestado A, Brollo M, Naline E, Victoni T, Longchamp E, Tenor H, Grassin-Delyle S, Devillier P.

(13) Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressivenessJournal of translational medicineSeptember 9, 2019Ruiz-Plazas X, Rodríguez-Gallego E, Alves M, Altuna-Coy A, Lozano-Bartolomé J, Portero-Otin M, García-Fontgivell JF, Martínez-González S, Segarra J, Chacón MR.

(14) Excessive neutrophil levels in the lung underlie the age-associated increase in influenza mortalityMucosal immunologyMarch 1, 2019Kulkarni U, Zemans RL, Smith CA, Wood SC, Deng JC, Goldstein DR.

(15) Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5TheranosticsJanuary 1, 2019Giuliano S, Dufies M, Ndiaye PD, Viotti J, Borchiellini D, Parola J, Vial V, Cormerais Y, Ohanna M, Imbert V, et al.

(16) Serum from patients with chronic obstructive pulmonary disease induces senescence-related phenotype in bronchial epithelial cellsScientific reportsAugust 28, 2018Kuźnar-Kamińska B, Mikuła-Pietrasik J, Witucka A, Romaniuk A, Konieczna N, Rubiś B, Książek K, Tykarski A, Batura-Gabryel H.

(17) The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2Molecular cellFebruary 16, 2017Hartwig T, Montinaro A, von Karstedt S, Sevko A, Surinova S, Chakravarthy A, Taraborrelli L, Draber P, Lafont E, Arce Vargas F, et al.

(18) Pulmonary Epithelial TLR4 Activation Leads to Lung Injury in Neonatal Necrotizing EnterocolitisJournal of immunology (Baltimore, Md. : 1950)August 1, 2016Jia H, Sodhi CP, Yamaguchi Y, Lu P, Martin LY, Good M, Zhou Q, Sung J, Fulton WB, Nino DF, et al.

(19) IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancerJournal of experimental & clinical cancer research : CRNovember 25, 2013Kachroo P, Lee MH, Zhang L, Baratelli F, Lee G, Srivastava MK, Wang G, Walser TC, Krysan K, Sharma S, et al.

(20) IL-17A and TNF-α exert synergistic effects on expression of CXCL5 by alveolar type II cells in vivo and in vitroJournal of immunology (Baltimore, Md. : 1950)March 1, 2011Liu Y, Mei J, Gonzales L, Yang G, Dai N, Wang P, Zhang P, Favara M, Malcolm KC, Guttentag S, et al.

Be the First to Write a Review!

CXCL5/ENA-78 ELISA

Human CXCL5/ENA-78 DuoSet ELISA

CXCL5/ENA-78 ELISA from R&D Systems, a Bio-Techne Brand

Specifications/Features

R&D Systems, a Bio-Techne Brand

Citations (25)

Reviews

CXCL5/ENA-78 ELISA from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map